Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly
Retrieved on:
Thursday, August 11, 2022
Multimedia, InterContinental, Hematology, Obesity, CEO, NYSE, Senior, Private Securities Litigation Reform Act, Growth, Leadership, Knowledge, Eli Lilly and Company, Compliance, Cancer, LLY, BMS, Patient, Executive Committee, James Lillie, Alzheimer's disease, Lists of diseases, Human resources, Retirement, Fry, Biotechnology, CHRO, Diversity, Novartis, Form 10-K, Chemistry, Business administration, Culture, Howard University, Solution, Bristol Myers Squibb, Master of Business Administration, Management, Pharmaceutical industry, Indiana University, Lilly
INDIANAPOLIS, Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for Loxo@Lilly.
Key Points:
- After more than 35 years at Lilly, Stephen Fry, senior vice president, human resources and diversity, will retire at the end of 2022.
- His depth of knowledge about our business, commitment to Lilly, and expertise in human resources will be missed by employees, management, and our board.
- Eric Dozier, currently vice president and chief commercial officer for Loxo@Lilly, is being promoted to succeed Fry as senior vice president, human resources and diversity.
- There can be no assurance that the leadership changes will achieve Lilly's objectives or that Lilly will execute its strategy as planned.